Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Khaled M Musallam

Showing results (1-10 of 203) with videos related to

Pageof 21
Sort By:
Cureus|December 30, 2024
How I Write Manuscripts for Peer-Reviewed Medical JournalsKhaled M Musallam
Expert Review of Hematology|August 2, 2011
Managing unresponsiveness or intolerance to deferasirox therapy: a tale of two dosesKhaled M Musallam
American Journal of Hematology|June 19, 2025
Luspatercept in Transfusion-Dependent β-Thalassemia: The Benefit Is Real, and So Are the RisksKhaled M Musallam
The Lancet. Haematology|February 13, 2025
What we now BELIEVE is achievable with luspatercept in transfusion-dependent β-thalassaemiaKhaled M Musallam
The Lancet. Haematology|April 4, 2026
Scientific progress in the shadow of regional instabilityKhaled M Musallam
Hemoglobin|June 9, 2026
Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell DiseaseKhaled M Musallam, Biree Andemariam
Haematologica|February 2, 2011
Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia majorKhaled M Musallam, Ali T Taher
Hemoglobin|September 14, 2011
Thrombosis in thalassemia: why are we so concerned?Khaled M Musallam, Ali T Taher
The New England Journal of Medicine|April 15, 2011
Iron-chelating therapy for transfusional iron overloadKhaled M Musallam, Ali T Taher
Hematology. American Society of Hematology. Education Program|December 7, 2024
Luspatercept: a treatment for ineffective erythropoiesis in thalassemiaKhaled M Musallam, Ali T Taher
Pageof 21

Showing results (1-10 of 203) with videos related to

Sort By:
Pageof 21
Cureus|December 30, 2024
How I Write Manuscripts for Peer-Reviewed Medical JournalsKhaled M Musallam
Expert Review of Hematology|August 2, 2011
Managing unresponsiveness or intolerance to deferasirox therapy: a tale of two dosesKhaled M Musallam
American Journal of Hematology|June 19, 2025
Luspatercept in Transfusion-Dependent β-Thalassemia: The Benefit Is Real, and So Are the RisksKhaled M Musallam
The Lancet. Haematology|February 13, 2025
What we now BELIEVE is achievable with luspatercept in transfusion-dependent β-thalassaemiaKhaled M Musallam
The Lancet. Haematology|April 4, 2026
Scientific progress in the shadow of regional instabilityKhaled M Musallam
Hemoglobin|June 9, 2026
Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell DiseaseKhaled M Musallam, Biree Andemariam
Haematologica|February 2, 2011
Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia majorKhaled M Musallam, Ali T Taher
Hemoglobin|September 14, 2011
Thrombosis in thalassemia: why are we so concerned?Khaled M Musallam, Ali T Taher
The New England Journal of Medicine|April 15, 2011
Iron-chelating therapy for transfusional iron overloadKhaled M Musallam, Ali T Taher
Hematology. American Society of Hematology. Education Program|December 7, 2024
Luspatercept: a treatment for ineffective erythropoiesis in thalassemiaKhaled M Musallam, Ali T Taher
Pageof 21